Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): A phase-II randomized clinical trial

Trials

Volumn 10, Issue , 2009, Pages

  Montoya, Carlos J ^a   Jaimes, Fabian ^a   Higuita, Edwin A ^a   Convers Páez, Sandra ^a   Estrada, Santiago ^b   Gutierrez, Francisco ^a   Amariles, Pedro ^a   Giraldo, Newar ^c   Peñaloza, Cristina ^d   Rugeles, Maria T ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Laboratorio Clinico Congregacion Mariana   (Colombia)

^c Humax Pharmaceutical   (Colombia)

^d Laproff Laboratories   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHOLESTEROL; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ANTIVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION; DRUG EFFECT; METHODOLOGY; REGRESSION ANALYSIS;

ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; LOVASTATIN; REGRESSION ANALYSIS; RESEARCH DESIGN;

EID: 67650398334     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-41     Document Type: Article

References (67)

1. UNAIDS and WHO AIDS epidemic update 2007 Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2007.
2. Instituto Nacional de Salud Programa Nacional de Prevención y control ITS/SIDA. Colombia 1983-2002 Bogotá: Instituto Nacional de Salud, Ministerio de Salud de la República de Colombia 2003.
3. Giorgi JV Liu Z Hultin LE Cumberland WG Hennessey K Detels R Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up J Acquir Immune Defic Syndr 1993, 6:904-912. 7686224
4. Hazenberg MD Otto SA van Benthem BHB Roos MTL Coutinho RA Lange JMA et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS AIDS 2003, 17:1881-1888. 12960820
5. Cohen DE Walker BD Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection Clin Infect Dis 2001, 32:1756-1768. 11360218
6. Palella FJ Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 1998, 338:853-860. 9516219
7. Finzi D Hermankova M Pierson T Carruth LM Buck C Chaisson RE et al.: Identification of a reservoir for HIV-1 in patients on highly active retroviral therapy Science 1997, 278:1295-1300. 9360927
8. Panel on Antiretroviral Guidelines for Adult and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
9. Aberg JA Zackin RA Brobst SW Evans SR Alston BL Henry WK et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087 AIDS Res Hum Retroviruses 2005, 21:757-767. 16218799
10. Calza L Manfredi R Chiodo F Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART AIDS 2003, 17:851-859. 12660532
11. Fehr T Kahlert C Fierz W Joller-Jemelka HI Riesen WF Rickli H et al.: Statin-induced immunomodulatory effects on human T cells in vivo Atherosclerosis 2004, 175:83-90. 15186950
12. Yilmaz A Reiss C Tantawi O Weng A Stumpf C Raaz D et al.: HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: New implications for atherosclerosis Atherosclerosis 2004, 172:85-93. 14709361
13. Kwak B Mulhaupt F Veillard N Pelli G Mach F The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells Swiss Med Wkly 2001, 131:41-46. 11219190
14. Liao Z Cimakasky LM Hampton R Nguyen DH Hildreth JE Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1 AIDS Res Hum Retroviruses. 2001, 17(11):1009-1019. 11485618
15. del Real G Jimenez-Baranda S Lacalle RA Mira E Lucas P Gomez-Mouton C et al.: Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains J Exp Med 2002, 196:293-301. 2193941 12163558
16. del Real G Jimenez-Baranda S Mira E Lacalle RA Lucas P Gomez-Mouton C et al.: Statins inhibit HIV-1 infection by down-regulating Rho activity J Exp Med 2004, 200:541-547. 2211926 15314078
17. Giguere JF Tremblay MJ Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1 J Virol 2004, 78:12062-12065. 523291 15479847
18. Nabatov AA Pollakis G Linnemann T Paxton WA de Baar MP Statins Disrupt CCR5 and RANTES Expression Levels in CD4+ T Lymphocytes In Vitro and Preferentially Decrease Infection of R5 Versus X4 HIV-1 PLoS ONE 2007:e470. 1867858 17520029
19. Hakamada-Taguchi R Uehara Y Kuribayashi K Inhibition of hydroxymethylglutarylcoenzyme A reductase reduces Th1 development and promotes Th2 development Circ Res 2003, 93:948-956. 14563711
20. Shimada K Miyauchi K Daida H Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench Circulation 2004, 109:e213-e214. 15136515
21. Youssef S Stuve O Patarroyo JC The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 2002, 420:78-84. 12422218
22. Pasternak RC Smith SC Bairey-Merz CN Grundy SM Cleeman JI Lefant C ACC/ AHA/NHLBI clinical advisory on the use and safety of statins JACC 2002, 40:567-572. 12142128
23. Liao Z Roos JW Hildreth JE Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4 AIDS Res Hum Retroviruses 2000, 16:355-366. 10716373
24. Liang KY Zeger SL Regression analysis for correlate data Annu Rev Pub Health 1993, 14:43-68.
25. Zeger SL Liang KY An overview of methods for the analysis of longitudinal data Statistics in Medicine 1992, 11:1825-1839. 1480876
26. DiClemente RJ Wingood GM Harrington KF Lang DL Davies SL Hook EW Efficacy of an HIV prevention intervention for African American adolescent girls: A randomized controlled trial JAMA 2004, 292:171-179. 15249566
27. Illingworth DR Tobert JA HMG-CoA reductase inhibitors Adv Protein Chem 2001, 56:77-114. 11329860
28. Garcia PJ Pleiotropic effects of statins: Moving beyond cholesterol control Curr Atheroscler Rep 2005, 7:34-39. 15683600
29. Blanco-Colio LM Tunon J Martin-Ventura JL Egido J Anti-inflammatory and immunomodulatory effects of statins Kidney Int 2003, 63:12-23. 12472764
30. Kallen J Welzenbach K Ramage P Geyl D Kriwacki R Legge G Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain J Mol Biol 1999, 292:1-9. 10493852
31. Issekutz TB Inhibition of lymphocyte endothelial adhesion and in vivo lymphocyte migration to cutaneous inflammation by TA-3, a new monoclonal antibody to rat LFA-1 J Immunol 1992, 149:3394-3402. 1358970
32. Wallays G Ceuppens JL Ligation of leukocyte function-associated (LFA) molecule-1 provides an accessory signal for T-cell activation with pokeweed mitogen Scand J Immunol 1994, 39:137-143. 7905204
33. Vanhaecke J Van Cleemput J Van Lierde J Daenen W De Geest H Safety and efficacy of lowdose simvastatin in cardiac transplant recipients treated with cyclosporine Transplantation 1994, 58:42-45. 8036706
34. Vaughan CJ Delanty N Neuroprotective properties of statins in cerebral ischemia and stroke Stroke 1999, 30:1969-1973. 10471452
35. Moncunill G Negredo E Bosch L Vilarrasa J Witvrouw M Llano A et al.: Evaluation of the anti-HIV activity of statins AIDS 2005, 19:1697-1700. 16184043
36. Sklar PA Masur H Grubb JR Voell J Witek J Ono A et al.: Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy AIDS 2005, 19:1109-1111. 15958846
37. Manfredi R Calza L Chiodo F Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART AIDS 2006, 20:455-457. 16439881
38. Waters L Stebbing J Jones R Mandalia S Bower M Stefanovic M et al.: The effect of statins on HIV rebound and blips J Acquir Immune Defic Syndr 2005, 39:637-638. 16044021
39. Goot van der FG Harder T Raft membrane domains: From a liquid-ordered membrane phase to a site of pathogen attack Semin Immunol 2001, 13:89-97. 11308292
40. Manes S del Real g Lacalle RA Lucas P Gomez-Mouton C Sanchez-Palomino S et al.: Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection EMBO Rep 2000, 1:190-196. 1084257 11265761
41. Moore JP Trkola A Dragic T Co-receptors for HIV-1 entry Curr Opin Immunol 1997, 9:551-562. 9287172
42. Nguyen DH Taub DD Inhibition of chemokine receptor function by membrane cholesterol oxidation Exp Cell Res 2003, 291:36-45. 14597406
43. Gummuluru S Rogel M Stamatatos L Emerman M Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DCSIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway J Virol 2003, 77:12865-12874. 262553 14610207
44. Guyader M Kiyokawa E Abrami L Turelli P Trono D Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization J Virol 2002, 76:10356-10364. 136590 12239312
45. Viard M Parolini I Sargiacomo M Fecchi K Ramoni C Ablan S et al.: Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells J Virol 2002, 76:11584-11595. 136803 12388719
46. Vincent N Genin C Malvoisin E Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups Biochim Biophys Acta. 2002, 1567(1-2):157-164. 12488049
47. Saez-Cirion A Nir S Lorizate M Agirre A Cruz A Perez-Gil J et al.: Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring J Biol Chem 2002, 277:21776-21785. 11929877
48. Campbell SM Crowe SM Mak J Virion associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity AIDS 2002, 16:2253-2261. 12441796
49. Liao Z Graham DR Hildreth JE Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells AIDS Res Hum Retroviruses 2003, 19:675-687. 13678470
50. Fortin JF Cantin R Lamontagne G Tremblay M Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity J Virol 1997, 71:3588-3596. 191506 9094631
51. Nguyen DH Hildreth JE Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts J Virol 2000, 74:3264-3272. 111827 10708443
52. Zheng YH Plemenitas A Fielding CJ Peterlin BM Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions Proc Natl Acad Sci USA 2003, 1000:8460-8465.
53. Wang JK Kiyokawa E Verdin E Trono D The Nef protein of HIV-1 associates with rafts and primes T cells for activation Proc Natl Acad Sci U S A. 2003, 100(14):8460-8465. 26674 10618429
54. Butini L De Fougerolles AR Vaccarezza M Graziosi C Cohen DI Montroni M et al.: Intercellular adhesion molecules (ICAM)-1, ICAM-2, and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation Eur J Immunol 1994, 24:2191-2195. 7916296
55. Tremblay MJ Fortin JF Cantin R The acquisition of host-encoded proteins by nascent HIV-1 Immunol Today 1998, 19:346-351. 9709501
56. Park SW Royal W Semba RD Wiegand GW Griffin DE Expression of adhesion molecules and CD28 on T lymphocytes during human immunodeficiency virus infection Clin Diagn Lab Immunol 1998, 5:583-587. 95622 9665971
57. Pearce-Pratt R Phillips DM Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus Biol Reprod 1993, 48:431-445. 8452921
58. Schrier RD McCutchan JA Wiley CA Mechanisms of immune activation of human immunodeficiency virus in monocytes/macrophages J Virol 1993, 67:5713-5720. 237987 8371336
59. Fujiwara M Tsunoda R Shigeta S Yokota T Baba M Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction J Virol 1999, 73:3603-3607. 104134 10196251
60. Tsunetsugu-Yokota Y Yasuda S Sugimoto A Yagi T Azuma M Yagita H et al.: Efficient virus transmission from dendritic cells to CD4+ T cells in response to antigen depends on close contact through adhesion molecules Virology 1997, 239:259-268. 9434717
61. Hioe CE Chien PC Lu C Springer TA Wang XH Bandres J et al.: LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission J Virol 2001, 75:1077-1082. 114007 11134324
62. Hildreth JE Orentas RJ Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation Science 1989, 244:1075-1078. 2543075
63. Graaf MR Richel DJ van Noorden CJ Guchelaar HJ Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer Cancer Treat Rev 2004, 30:609-641. 15531395
64. Raggatt LJ Partridge NC HMG-CoA reductase inhibitors as immunomodulators: Potential use in transplant rejection Drugs 2002, 62:2185-2191. 12381218
65. Maziere JC Landureau JC Giral P Auclair M Fall L Lachgar A Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium Biomed Pharmacother 1994, 48:63-67. 7522603
66. Leung BP Sattar N Crilly A Prach M Mc-Carey DW Payne H et al.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis J Immunol 2003, 170:1524-1530. 12538717
67. McKay A Leung BP McInnes IB Thomson NC Liew FY A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma J Immunol 2004, 172:2903-2908. 14978092